Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

Detalles Bibliográficos
Autores principales: Swanson, Chad J., Zhang, Yong, Dhadda, Shobha, Wang, Jinping, Kaplow, June, Lai, Robert Y. K., Lannfelt, Lars, Bradley, Heather, Rabe, Martin, Koyama, Akihiko, Reyderman, Larisa, Berry, Donald A., Berry, Scott, Gordon, Robert, Kramer, Lynn D., Cummings, Jeffrey L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123682/
https://www.ncbi.nlm.nih.gov/pubmed/35598024
http://dx.doi.org/10.1186/s13195-022-00995-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123682/
https://www.ncbi.nlm.nih.gov/pubmed/35598024
http://dx.doi.org/10.1186/s13195-022-00995-9

Ejemplares similares